Month: June 2025

OSLO, Norway (3 June 2025) – TGS, a leading provider of energy data and intelligence, attends investor meetings at the EAGE industry conference today. The presentation the company is using includes one new slide (#8 in the presentation) showing booked positions for streamer and OBN for the next quarters.  The presentation can be downloaded from www.newsweb.no or www.tgs.com. For more information, visit TGS.com or contact: Bård Stenberg VP IR & Communication Mobile: +47 992 45 235 investor@tgs.comAttachmentEAGE presentation

Geneva, Switzerland, June 3, 2025 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1.   Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 2024 2.   Consultative vote on the Compensation Report for the business year 2024 3.   Appropriation of the results 4.   Discharge of the members of the Board of Directors and of the Executive Management 5.   Re-elections of the members of the Board of Directors and re-election...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors in a poster presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. Alrizomadlin is the first MDM2-p53 inhibitor to enter clinical development in China and a key investigational drug candidate in Ascentage Pharma’s apoptosis-targeted pipeline with global first-in-class potential. The ASCO Annual Meeting showcases the most cutting-edge...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naïve (TN) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. As Ascentage Pharma returns...

Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-’568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025. Nxera previously announced the initiation of the Phase 3 registrational program of NBI-’568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-’568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll...

BOCA RATON, FL, June 02, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a record-setting May 2025 highlighted by significant advancements across its validator infrastructure, treasury growth, and strategic integrations. Key May 2025 Highlights:Record SOL Purchases: DeFi Dev Corp. achieved its largest monthly SOL purchase, reinforcing its strategy to build the world’s leading publicly traded Solana treasury.Validator Launches: The Company announced a validator partnership with Bonk, Solana’s largest memecoin community, adding to its expanding network of revenue-generating validators.Kamino Integration: DeFi Dev Corp. signed a letter of intent with Kamino Finance,...

Taipei, Taiwan, June 02, 2025 (GLOBE NEWSWIRE) — Semilux International Ltd. (NASDAQ:SELX) (“SELX” or the “Company”) announced that it received a delinquency notification letter on May 27, 2025 (the “Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the “Nasdaq”) notifying the Company that it is no longer in compliance with the Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) for continued listing due to its failure to timely file its annual report on Form 20-F for the year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. In accordance with Nasdaq’s listing rules, the Company has 60 calendar days after the Deficiency Letter to...

VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company’s board of directors (the “Board”) at the Meeting and listed in the Company’s Management Information Circular dated April 25, 2025, were elected. The directors will remain in office until the next annual meeting of shareholders, or until their successors are...

CALGARY, Alberta, June 02, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce the appointment of Alberto Consuegra to the Board of Directors (the “Board”). Effective June 1, 2025, Alberto Consuegra has been appointed to the Board as an independent director. Alberto has more than 30 years of experience in the energy sector. Most recently, Mr. Consuegra served as the Chief Operating Officer of Ecopetrol, Colombia’s national oil company, and for a period of time acted as the Company’s interim Chief Executive Officer. He has also served as the President of Cenit Transporte y Logística de Hidrocarburos S.A.S., the Vice President of Supply and Services of Ecopetrol, and held several executive positions at Equion Energia Ltd. and BP Exploration. Mr. Consuegra graduated from Universidad...